News and Announcements
MHRA Approves Commencement of OncoSil’s Study of Pancreatic Cancer Clinical Study in UK
- Published February 21, 2017 11:32AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
OncoSil Medical Limited (ASX:OSL) is a medical device company seeking to advance radiation for cancer patients.
KEY TAKEAWAYS:
- Medical device company is mainly focused on localised treatments for patients with pancreatic and liver cancer.
- MHRA has approved the commencement of the Pancreatic Cancer Clinical Study in the UK.
OncoSil Medical Limited is a clinical-stage Australian Lifesciences company with the aim to develop and provide technologies for safer medical radiation treatments.
“The comprehensive MHRA review conducted over the past two months, focused on pre-clinical, clinical data as well study design. Approval was granted with no objections raised.
Daniel Kenny, CEO commented:
We are delighted with this news, which is a further endorsement of our clinical data package and allows OncoSil Medical to commence Clinical Studies in the UK.”
OncoSil Medical hopes with treatment of OncoSil™ it will deliver a more concentrated localised beta radiation compared to external beam radiation. OncoSil Medical has conducted four clinical studies with encouraging results on tolerability, safety and efficacy.
To view the full ASX Announcement, please click here.
Company Updates
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Asset over thematic: Centuria’s Andrew Essey warns against ‘blanket strategies’ as global capital eyes Australia
Relying solely on broad macroeconomic trends is the single biggest mistake property investors make today. Centuria Capital CIO Andrew Essey explains why asset-level “lettability” always trumps the overarching sector thematic, and reveals where global institutional capital is quietly pivoting to capture high-octane returns.
Backed By Leading Investment Groups and Family Offices
